Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity

被引:0
|
作者
Tomohiko Kimura
Atsushi Obata
Masashi Shimoda
Ikki Shimizu
Gabriela da Silva Xavier
Seizo Okauchi
Hidenori Hirukawa
Kenji Kohara
Tomoatsu Mune
Saeko Moriuchi
Arudo Hiraoka
Kentaro Tamura
Genta Chikazawa
Atsuhisa Ishida
Hidenori Yoshitaka
Guy A. Rutter
Kohei Kaku
Hideaki Kaneto
机构
[1] Endocrinology and Metabolism,Division of Diabetes
[2] Kawasaki Medical School,Department of Diabetes
[3] Sakakibara Heart Institute,Section of Cell Biology and Functional Genomics, Department of Medicine
[4] Imperial College London,Department of Cardiovascular Surgery
[5] Sakakibara Heart Institute,Department of General Internal Medicine 1
[6] Kawasaki Hospital,undefined
[7] Kawasaki Medical School,undefined
来源
Scientific Reports | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
It has been thought that incretin signaling prevents arteriosclerosis, and very recently anti-arteriosclerotic effects through GLP-1 receptor were finally demonstrated in clinical human study. The purpose of this study was to investigate how vascular GLP-1 receptor expression is influenced in human subjects. First, we evaluated GLP-1 receptor expression in human arteries in immunostaining. Next, we separated the artery into the intima and media, and evaluated gene expression levels of various factors. We divided the subjects into obesity and non-obesity group and compared their expression levels between them. Finally, we evaluated which factors determine vascular GLP-1 receptor expression. GLP-1 receptor expression in intima and media was lower in obesity group compared to non-obesity group which was correlated with the alteration of TCF7L2 expression. Multiple regression analyses showed that BMI was an independent determining factor for GLP-1 receptor expression in the intima and media. Furthermore, using small interfering RNA method and TCF7L2-EGFP adenovirus, we showed that TCF7L2 was involved in GLP-1 receptor expression in human vascular cells. Taken together, vascular GLP-1 receptor and TCF7L2 expression was significantly down-regulated in human subjects with obesity. In addition, it is likely that TCF7L2 functions as a modulator of vascular GLP-1 receptor expression.
引用
收藏
相关论文
共 50 条
  • [41] GLP-1 analogue recovers impaired insulin secretion from human islets treated with palmitate via down-regulation of SOCS2
    Chowdhury, Azazul Islam
    Bergsten, Peter
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 439 (0C) : 194 - 202
  • [42] GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
    Koerner, Meike
    Stoeckli, Martin
    Waser, Beatrice
    Reubi, Jean Claude
    JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (05) : 736 - 743
  • [43] The genomic organization of the human GLP-1 receptor gene
    Wilmen, A
    Walkenbach, A
    Füller, P
    Lankat-Buttgereit, B
    Göke, R
    Göke, B
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 (04) : 299 - 302
  • [44] Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the Diet-Induced Obesity Rat Model be Important in Liver Metabolism?
    Cevik, Neslihan
    Nacarkahya, Gulper
    Gurgul, Serkan
    Horozoglu, Cem
    EXPERIMED, 2024,
  • [45] Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
    Wharton, Sean
    Blevins, Thomas
    Connery, Lisa
    Rosenstock, Julio
    Raha, Sohini
    Liu, Rong
    Ma, Xiaosu
    Mather, Kieren J.
    Haupt, Axel
    Robins, Deborah
    Pratt, Edward
    Kazda, Christof
    Konig, Manige
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (10): : 877 - 888
  • [46] Obesity and heart failure-the role of GLP-1 receptor agonists
    Simonis, Gregor
    Schatz, Ulrike
    HERZ, 2025,
  • [47] GLP-1/glucagon receptor co-agonism for treatment of obesity
    Miguel A. Sánchez-Garrido
    Sara J. Brandt
    Christoffer Clemmensen
    Timo D. Müller
    Richard D. DiMarchi
    Matthias H. Tschöp
    Diabetologia, 2017, 60 : 1851 - 1861
  • [48] Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
    Strong, Jennifer
    Driscoll, Marcia S.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2025, 26 (02) : 175 - 182
  • [49] GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk
    Liuzzo, Giovanna
    Galiuto, Leonarda
    EUROPEAN HEART JOURNAL, 2021, 42 (17) : 1652 - 1653
  • [50] Efficacy and Tolerability of GLP-1 Receptor Agonists in Children and Adolescents with Obesity
    Ryan, Paul
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 79 - 79